Drug intelligence / Profile preview

HCP-1803

Development stage: Phase 2
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HCP-1803 is an oral small molecule drug under development by Hanmi Pharmaceutical for the treatment of essential (idiopathic) hypertension. It is currently in Phase 3 clinical trials and has not yet been approved in any country. The precise mechanism of action for HCP-1803 has not been publicly disclosed. The drug is being evaluated as a potential new therapy to lower blood pressure in adults with essential hypertension[1][2][4][5].

Beyond the preview

Go deeper on HCP-1803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP-1803.

Explore the full profile